ArticleCancer reports (Hoboken, N.J.)2026

Durable Intracranial Response to Sacituzumab Tirumotecan in HER2-Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report.

Guang-Liang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.